Compare Cipla with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs TORRENT PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA TORRENT PHARMA CIPLA/
TORRENT PHARMA
 
P/E (TTM) x 29.1 35.1 82.9% View Chart
P/BV x 4.1 8.9 46.3% View Chart
Dividend Yield % 0.5 0.7 72.5%  

Financials

 CIPLA   TORRENT PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-20
TORRENT PHARMA
Mar-19
CIPLA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs5861,964 29.8%   
Low Rs3571,245 28.7%   
Sales per share (Unadj.) Rs207.0453.4 45.7%  
Earnings per share (Unadj.) Rs18.625.8 72.1%  
Cash flow per share (Unadj.) Rs33.262.3 53.2%  
Dividends per share (Unadj.) Rs4.0017.00 23.5%  
Dividend yield (eoy) %0.81.1 80.1%  
Book value per share (Unadj.) Rs195.5279.2 70.0%  
Shares outstanding (eoy) m806.35169.22 476.5%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.33.5 64.3%   
Avg P/E ratio x25.362.2 40.7%  
P/CF ratio (eoy) x14.225.8 55.1%  
Price / Book Value ratio x2.45.7 41.9%  
Dividend payout %21.565.9 32.6%   
Avg Mkt Cap Rs m379,912271,513 139.9%   
No. of employees `00025.813.6 190.1%   
Total wages/salary Rs m30,27014,038 215.6%   
Avg. sales/employee Rs Th6,459.65,642.6 114.5%   
Avg. wages/employee Rs Th1,171.21,032.4 113.5%   
Avg. net profit/employee Rs Th580.2320.9 180.8%   
INCOME DATA
Net Sales Rs m166,94976,728 217.6%  
Other income Rs m3,442571 603.3%   
Total revenues Rs m170,39177,299 220.4%   
Gross profit Rs m32,06019,831 161.7%  
Depreciation Rs m11,7476,177 190.2%   
Interest Rs m1,9745,038 39.2%   
Profit before tax Rs m21,7829,187 237.1%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m6,3121,254 503.6%   
Profit after tax Rs m14,9954,363 343.7%  
Gross profit margin %19.225.8 74.3%  
Effective tax rate %29.013.6 212.4%   
Net profit margin %9.05.7 158.0%  
BALANCE SHEET DATA
Current assets Rs m117,03850,375 232.3%   
Current liabilities Rs m43,93151,653 85.1%   
Net working cap to sales %43.8-1.7 -2,629.5%  
Current ratio x2.71.0 273.2%  
Inventory Days Days9692 104.0%  
Debtors Days Days8568 124.6%  
Net fixed assets Rs m107,42483,648 128.4%   
Share capital Rs m1,613846 190.6%   
"Free" reserves Rs m156,01846,397 336.3%   
Net worth Rs m157,63047,244 333.7%   
Long term debt Rs m23,69339,129 60.6%   
Total assets Rs m236,626141,209 167.6%  
Interest coverage x12.02.8 426.3%   
Debt to equity ratio x0.20.8 18.1%  
Sales to assets ratio x0.70.5 129.8%   
Return on assets %7.26.7 107.7%  
Return on equity %9.59.2 103.0%  
Return on capital %12.812.3 104.1%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,03622,103 253.5%   
Fx outflow Rs m6,7645,522 122.5%   
Net fx Rs m49,27216,581 297.2%   
CASH FLOW
From Operations Rs m30,68517,981 170.7%  
From Investments Rs m1,040-2,413 -43.1%  
From Financial Activity Rs m-29,488-13,145 224.3%  
Net Cashflow Rs m2,3402,380 98.3%  

Share Holding

Indian Promoters % 16.0 71.5 22.4%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 7.0 173.8%  
FIIs % 23.7 12.6 188.1%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 8.8 297.7%  
Shareholders   161,166 26,511 607.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SANOFI INDIA  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT PHARMOVA   

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 441 Points Lower; Nifty Settles Below 15,000-Mark(Closing)

Indian share markets witnessed huge selling during closing hours today and ended their day lower.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

How Much Money For Day Trading?(Fast Profits Daily)

Feb 22, 2021

In this video, I'll show you how to allocate your capital as a day trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Mar 5, 2021 (Close)

TRACK CIPLA

CIPLA - NEULAND LABS COMPARISON

COMPARE CIPLA WITH

MARKET STATS